T Vilsbøll, T Krarup, CF Deacon, S Madsbad, JJ Holst - Diabetes, 2001 - Am Diabetes Assoc Incretin hormones importantly enhance postprandial insulin secretion but are rapidly degraded
to inactive metabolites by ubiquitous dipeptidyl peptidase IV. The concentrations of the intact
biologically active hormones remain largely unknown. Using newly developed assays for ... Cited by 300 - Related articles - BL Direct - All 4 versions
- ►nih.gov [PDF] MA Nauck, MM Heimesaat, C Orskov, JJ … - Journal of Clinical …, 1993 - pubmedcentral.nih.gov In type-2 diabetes, the overall incretin effect is reduced. The present investigation was designed
to compare insulinotropic actions ofexogenous incretin hormones (gastric inhibitory pep- tide
IGIPI and glucagon-like peptide 1 [GLP-1j 17-36 amidel) in nine type-2 diabetic patients ( ... Cited by 505 - Related articles - BL Direct - All 8 versions
- ►endojournals.org MB Toft-Nielsen, MB Damholt, S Madsbad, LM … - Journal of Clinical …, 2001 - Endocrine Soc To elucidate the causes of the diminished incretin effect in type 2 diabetes mellitus we investigated
the secretion of the incretin hormones, glucagon-like peptide-1 and glucose- dependent insulinotropic
polypeptide and measured nonesterified fatty acids, and plasma concentrations of insulin, ... Cited by 270 - Related articles - BL Direct - All 6 versions
M Nauck, F Stöckmann, R Ebert, W Creutzfeldt - Diabetologia, 1986 - Springer Summary. Integrated incremental immunoreactive insulin and connecting peptide responses
to an oral glucose load of 50 g and an "isoglycaemic" intravenous glucose infusion, respec-
tively, were measured in 14 Type 2 (non-insulin-dependent) diabetic patients and 8 age- ... Cited by 364 - Related articles - All 3 versions
T Vilsbøll, T Krarup, S Madsbad, J Holst - Diabetologia, 2002 - Springer Aims/hypothesis. Glucagon-like-peptide-1 (GLP-1) is strongly insulinotropic in patients with Type
II (non- insulin-dependent) diabetes mellitus, whereas glu- cose-dependent insulinotropic polypeptide
(GIP) is less effective. Our investigation evaluated “early” (protocol 1) – and “late phase” ( ... Cited by 135 - Related articles - BL Direct - All 4 versions
- ►endojournals.org CF Deacon, MA Nauck, J Meier, K Hucking, JJ … - Journal of Clinical …, 2000 - Endocrine Soc Gastric inhibitory polypeptide (GIP) is susceptible to degradation, but only recently has dipeptidyl
peptidase IV been identified as the enzyme responsible. Most RIAs recognize both intact
GIP-(1–42) and the noninsulinotropic N-terminally truncated metabolite, GIP-(3–42), ... Cited by 174 - Related articles - BL Direct - All 4 versions
M Zander, S Madsbad, JL Madsen, JJ Holst - The Lancet, 2002 - Elsevier 20 patients with type 2 diabetes were alternately assigned continuous subcutaneous infusion
of GLP-1 (n=10) or saline (n=10) for 6 weeks. Before (week 0) and at weeks 1 and 6, they underwent
β-cell function tests (hyperglycaemic clamps), 8 h profiles of plasma glucose, insulin, C- ... Cited by 618 - Related articles - BL Direct - All 9 versions
- ►endojournals.org MA Nauck, MM Heimesaat, K Behle, JJ Holst, … - Journal of Clinical …, 2002 - Endocrine Soc Nine healthy volunteers with normal oral glucose tolerance received infusions of regular insulin
(1 mU·kg -1 ·min -1 ) over 360 min on two occasions in the fasting state. Capillary glucose concentrations
were clamped at plateaus of 4.3, 3.7, 3.0, and 2.3 mmol/liter for 90 min each (stepwise ... Cited by 161 - Related articles - BL Direct - All 4 versions
LL Kjems, JJ Holst, A Vølund, S Madsbad - Diabetes, 2003 - Am Diabetes Assoc The intestinally derived hormone glucagon-like peptide 1 (GLP-1) (7-36 amide) has potent effects
on glucose-mediated insulin secretion, insulin gene expression, and β-cell growth and
differentiation. It is, therefore, considered a potential therapeutic agent for the treatment of ... Cited by 139 - Related articles - BL Direct - All 5 versions
- ►endojournals.org T Vilsboll, H Agerso, T Krarup, JJ Holst - Journal of Clinical Endocrinology …, 2003 - Endocrine Soc We have previously shown that type 2 diabetic patients have decreased plasma concentrations
of glucagon-like peptide 1 (GLP-1) compared with healthy subjects after ingestion of a standard
mixed meal. This decrease could be caused by differences in the metabolism of GLP-1. ... Cited by 125 - Related articles - BL Direct - All 6 versions
